Hikma on the lookout for new acquisitions; Apotex submits FDA application for Neulasta copycat;

@FiercePharma: New deer vaccine against mad-cow-like disease may help people too. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICMYI from FiercePharmaManufacturing: AstraZeneca targets U.K. plant for closure. Report | Follow @EricPFierce

@CarlyHFierce: #ICYMI: Deal-happy Actavis eyes Spain's Almirall for European growth. Story | Follow @CarlyHFierce

> Generic injectables maker Hikma is reportedly scouting out new acquisitions. Story (sub. req.)

> Apotex submitted an application to the FDA for a copycat of Amgen's ($AMGN) blockbuster Neulasta. More

> Foreign drugmakers in Korea are rolling out early retirement programs to cut jobs amid sluggish sales and restructuring. Story

> Cardinal Health is building an Indianapolis, IN-based plant to manufacture and distribute a new radioactive cancer treatment from Bayer. Story

> Glenmark Pharma is planning to expand its footprint in the U.S. by launching more generic copycats. More

> Eli Lilly ($LLY) won EU approval to market its stomach cancer drug Cyramza. Story

Medical Device News

@FierceMedDev: ICYMI Friday: Private equity firm backs Sonoma Orthopedic with $12M to get ankle implant to market. Story | Follow @FierceMedDev

@EmilyWFierce: ICYMI: U.S. appeals court reduces damages Zimmer must pay Stryker in surgical cleaning wand patent suit. Reuters story | Follow @EmilyWFierce

> Roche continues diagnostics winning streak with Bina Technologies acquisition. News

> NIH launches crowdsourcing challenge to commercialize its neurological medical devices. More

> Medtronic reaches another milestone in developing its artificial pancreas. Article

Biotech News

@FierceBiotech: Achillion shares rocket up as hep C drug scores a quick 6-week cure. News | Follow @FierceBiotech

@JohnCFierce: My schedule at #JPM15 is now officially packed. Thanks for all the invites. The industry is headed to San Fran. | Follow @JohnCFierce

@DamianFierce: Here's the packaging for $ABBV's Viekira, with handy instructions for each of its four pills. Image | Follow @DamianFierce

> Cubist scores another FDA nod on the eve of its $9.5B Merck merger. Article

> Back from the scrap heap, BioCryst wins OK for IV flu drug. News

> J&J steps up with $700M deal for MacroGenics' blood cancer drug, shares spike. Article

> AbbVie wins blockbuster hep C approval, starts wheeling and dealing on price. Report

CRO News

> Evotec banks $10M from its risk-sharing research projects. News

> PPD partners up with ERT for data collection. Story

> WuXi reaches into the biopharma hubs of Boston and San Francisco. More

> Poland's KCR expands its Euro reach with latest deal. Article

> After CEO's death, Health Decisions brings in a Quintiles vet to lead its transition. Report

Animal Health News

> Zoetis hikes dividend under continued pressure from activist investor Ackman. Report

> Aratana Therapeutics starts new canine study; reports good results on another. News

> Lilly's Elanco disputes local paper's allegations of unsafe pet meds. More

> Putney continues winning streak with launch of generic chewable Rimadyl. Article

> Bayer casts off equine drugs with 'no strategic relevance' to Sanofi's Merial. Story

And Finally… Some states that did not opt to expand their Medicaid programs as part of the Affordable Care Act are seeing marked enrollment increases in state health insurance. Story (sub. req.)

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.